The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Blueprint Medicines Corp shares valued at $419,891 were purchased by MICHAEL LANDSITTEL on Aug 15 ’24. At $95.23 per share, MICHAEL LANDSITTEL acquired 4,409 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Lee Philina sold 41,913 shares, netting a total of over 3,905,872 in proceeds. Following the sale of shares at $93.19 each, the insider now holds 34,729 shares.
Before that, Lee Philina had added 46,436 shares to its account. In a trade valued at $4,318,548, the Officer bought Blueprint Medicines Corp shares for $93.00 each.
As published in their initiating research note from Stephens on May 14, 2024, Blueprint Medicines Corp [BPMC] has been an Overweight and the price target has been revised to $140. Analysts at Leerink Partners upgraded the stock from ‘”an Underperform”‘ to ‘”a Market perform”‘ outlook in a report released in early May. As of October 27, 2023, Oppenheimer has increased its “Perform” rating to a “an Outperform” for BPMC. Earlier on August 21, 2023, Needham resumed its rating. Their recommendation was “a Buy” for BPMC stock.
Analyzing BPMC Stock Performance
During the last five days, there has been a surge of approximately 4.46%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 3.56%. Shares of the company reached a 52-week high of $121.90 on 07/16/24 and a 52-week low of $72.24 on 02/14/24. A 50-day SMA is recorded $106.70, while a 200-day SMA reached $90.92. Nevertheless, trading volume fell to 0.54 million shares from 0.68 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 94.50, which, if violated, would cause prices to drop to 93.47. In the upper region, resistance lies at 96.38. The next price resistance is at 97.23. RSI (Relative Strength Index) is 36.99 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.24, which suggests the price will decrease in the coming days. Percent R is at 73.51%, indicating bearish price movement. Stochastics%K at buying indicates that the stock is to be held.
